Publications
190
Citations
2,426
Est. group size
—
Recurring co-author estimate
Active years
20
Publishing since 2007
Hristos Z. Kaimakliotis conducts clinical research on cancers of the urinary tract, especially bladder cancer and upper tract urothelial carcinoma (cancers of the lining of the bladder, kidney, and ureter). The work spans new drug treatments (including immunotherapy and gel-based chemotherapy), improved diagnostic tools such as blue-light cystoscopy, and strategies to predict how patients respond to treatment. Much of this is done through multicenter clinical trials and patient registries.
Publication activity has been fairly steady across the decade, averaging around 13-14 papers per year over the last five years, with a notable spike in 2023.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- P56 REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY BY CISPLATIN ELIGIBILITY STATUS: A US MULTICENTER CHART REVIEW STUDY
Value in Health · 2026
- UTOPIA: A phase 3 trial of UGN-103, an intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Journal of Clinical Oncology · 2026
- IP30-20 MACHINE LEARNING–BASED PREDICTION OF PROGRESSION TO RADICAL NEPHROURETERECTOMY AFTER ENDOSCOPIC MANAGEMENT OF UPPER TRACT UROTHELIAL CARCINOMA
The Journal of Urology · 2026
- Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444).
Journal of Clinical Oncology · 2026
- IP12-13 LONG-TERM OUTCOMES OF TREATMENT OF RECURRENT OR NEW-ONSET LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA WITH UGN-101, A MITOMYCIN REVERSE THERMAL GEL
The Journal of Urology · 2025
- IP02-18 PERFORMANCE OF THE EORTC AND CUETO RISK PREDICTION MODELS IN CONTEMPORARY PATIENTS UNDERGOING TRANSURETHRAL RESECTION OF BLADDER TUMOR WITH BLUE LIGHT CYSTOSCOPY
The Journal of Urology · 2025
- IP02-10 PREDICTING RECURRENCE AND PROGRESSION IN CONTEMPORARY PATIENTS WITH NMIBC UNDERGOING BLUE LIGHT CYSTOSCOPY-AIDED TRANSURETHRAL RESECTION OF BLADDER TUMOR
The Journal of Urology · 2025
- LONG-TERM OUTCOMES OF PRIMARY CHEMOABLATION OF LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA (LG-UTUC) WITH UGN-101, A MITOMYCIN REVERSE THERMAL GEL
Urologic Oncology Seminars and Original Investigations · 2025
- Durability of response of UGN-101: Longitudinal follow up of multicenter study
Urologic Oncology Seminars and Original Investigations · 2025
- IP02-32 UPSTAGING AND RISK MIGRATION WITH BLUE LIGHT CYSTOSCOPY FOR NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM a PROSPECTIVE MULTICENTER REGISTRY
The Journal of Urology · 2025
- Upstaging and risk migration with blue light cystoscopy for non–muscle-invasive bladder cancer: Results from a prospective multi-center registry.
Journal of Clinical Oncology · 2025
- The uTRACT registry: A single-arm, multicenter, prospective, and retrospective registry study to evaluate the real-world use of UGN-101 in participants with upper tract urothelial carcinoma (UTUC) in the United States.
Journal of Clinical Oncology · 2025
- Outcomes of endoscopic management for upper tract urothelial carcinoma: A multi-center international cohort analysis
Urologic Oncology Seminars and Original Investigations · 2025
- Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer
Journal of Clinical Investigation · 2025
- PD41-12 EXPLORING RECURRENCE AFTER INITIAL RESPONSE TO UGN-101 INDUCTION IN EXPANDED SETTINGS
The Journal of Urology · 2024
- The Journal of Urology×35
- Urologic Oncology Seminars and Original Investigations×17
- Journal of Clinical Oncology×12
- Author eBooks×5
- Urology×4
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile